

DIADS, NIAID Phased Innovation Award Program Customer Satisfaction Survey  
**Web Survey Screenshots**

Login Page

NIH National Institute of Allergy and Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Please enter the email address where you received the survey invitation and your password provided in that email.

Email

Password

Next Page

0%



National Institute of  
Allergy and  
Infectious Diseases

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

The Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) has utilized the biphasic R21/R33 grant mechanism to support AIDS Vaccine Research and the Microbicide Innovation Program. Survey respondents are Principal Investigators (PIs) who received AIDS Vaccine Research (AVR) or Microbicide Innovations Program (MIP) phased innovation awards from FY 2006 through FY 2012.

The purpose of the survey is twofold:

- To determine grantees' overall satisfaction with the Phased Innovation Award R21/R33 grant funding mechanism; and
- To obtain information regarding key aspects of the funding mechanism that are particularly helpful or challenging.

Your answers to this survey will provide valuable information for the future of this program. The survey is voluntary, and results will only be reported in the aggregate.

Burden Disclosure: Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA# 0925-0668. Do not return the completed form to this address.

Previous Page

Next Page

2%



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Informed Consent Form

**Identification of Project** DIVISION OF AIDS, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES  
PHASED INNOVATION AWARD PROGRAM CUSTOMER SATISFACTION SURVEY

**Statement of Age of Subject** I state that I am at least 18 years of age, in good physical health, and wish to participate in research being conducted by the Division of AIDS of the National Institute of Allergy and Infectious Diseases, Rockville, MD 20852.

**Purpose** The purpose of this research is to assess grantees' overall satisfaction with the Phased Innovation Award R21/R33 grant funding mechanism and obtain information regarding key aspects of the funding mechanism that were particularly helpful or challenging.

**Procedures** Participants will be asked to access a web-based questionnaire and complete the questionnaire by a specific date. The total time involved, including instructions, will be no more than 15 minutes.

**Confidentiality** All information collected in this study will be kept secure to the extent permitted by law. I understand that the data I provide will be grouped with data that others provide for the purpose of reporting and presentation, and that my name will not be used.

**Risks** I understand that the risks of my participation are expected to be minimal in nature.

**Benefits, Freedom to Withdraw, & Ability to Ask Questions** I understand that this study is not designed to help me personally but that the investigators hope to learn about the grantees overall satisfaction with the Phased Innovation Award Program. The survey population will include Principal Investigators who received Phased Innovation awards. I am free to ask questions or withdraw from participation at any time and without penalty.

**Contact Information of Investigators** Name: Madelon Halula, PhD  
Office: Division of AIDS, National Institute of Allergy and Infectious Diseases  
Telephone: 301-402-2636  
Email: [mhalula@niaid.nih.gov](mailto:mhalula@niaid.nih.gov)

**Agreement to Consent \***

- I have read the information about this study, and I agree to participate in this survey.
- I have read the information about this study, and I do not wish to participate in this survey at this time.

Previous Page

Next Page

5%

**SECTION 1: FUNDING ANNOUNCEMENT**

Question 1

[Click here to save and continue survey later](#)



**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**FUNDING ANNOUNCEMENT**

How did you first hear about the R21/R33 funding announcement? (Please check all that apply.)

- NIH Guide
- NIAID Program Officer
- NIAID Newsletter
- NIAID Website or other NIAID resource
- Colleague
- Scientific meeting
- Other (Please specify)

Previous Page

Next Page

7%



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

### FUNDING ANNOUNCEMENT

How did you first hear about the R21/R33 funding announcement? (Please check all that apply.)

- NIH Guide
- NIAID Program Officer
- NIAID Newsletter
- NIAID Website or other NIAID resource
- Colleague
- Scientific meeting
- Other (Please specify)

Previous Page

Next Page

9%

SECTION 2: APPLICATION PROCESS

Question 3

Click here to save and continue survey later



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**APPLICATION PROCESS**

Did you contact the DAIDS Program Officer while developing your R21/R33 application?

- Yes
- No

Previous Page

Next Page







National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

How did you contact the Program Officer while developing your application? (Please check all that apply)

- Email
- Phone
- In person meeting
- Other (please specify)

My communications with the Program Officer during the application phase helped me to develop a stronger application than I would have otherwise.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page

14%

SECTION 3: MILESTONES REQUIREMENT

Question 4

Click here to save and continue survey later



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**MILESTONES REQUIREMENT**

Please rate your level of agreement with the following statements:  
(Please fill in one for each row.)

	Strongly Agree	Agree	Disagree	Strongly Disagree
I had a clear understanding of the use of milestones while writing my application.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The milestones in my awarded application changed significantly from those in my initial application.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The amount of input that I had in establishing the milestones for my awarded application was appropriate.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Previous Page

Next Page



[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

How satisfied were you with the process used to set milestones in the awarded application?

- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied

Previous Page

Next Page

18%

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

How would you improve the process used to set milestones?

Previous Page

Next Page

20%

SECTION 4: MILESTONES EFFECT ON RESEARCH

Question 7

Click here to save and continue survey later



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016


**MILESTONES EFFECT ON RESEARCH**

Please rate your level of agreement with the following statements:  
(Please fill in one for each row.)

	Strongly Agree	Agree	Disagree	Strongly Disagree
The milestones helped focus my research during the R21 phase.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The milestones discouraged innovative research during the R21 phase.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Having milestones helped me to be realistic about what I could accomplish during the R21 phase.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The milestones helped me move my research forward to completion.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Previous Page

Next Page



[Click here to save and continue survey later](#)



## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

### R21 BUDGET/GRANT PERIOD

Please rate your level of agreement with the following statements:  
(Please fill in one for each row.)

	Strongly Agree	Agree	Disagree	Strongly Disagree
The \$275,000 dollar limit in the R21 phase limited the research that I would have otherwise proposed in the first two years of an R01 grant.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The milestones in my awarded grant were too ambitious for the R21 budget.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Two years for the R21 phase was sufficient time to meet the milestones necessary to be eligible to transition to the R33 phase.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Previous Page

Next Page



SECTION 6: TRANSITION PROCESS

Question 9

Click here to save and continue survey later



National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

TRANSITION PROCESS

Did you transition from the R21 award and receive R33 funding?

- Yes
- No, I am still in the R21 Phase
- No

Previous Page

Next Page





National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

The reasons why I did not receive R33 funding were clearly explained to me.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page

30%



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

The transition process from R21 funding to R33 funding was efficient.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page





National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

From your experience, what was inefficient about the transition process from R21 funding to R33 funding?

[Previous Page](#)

[Next Page](#)





National Institute of  
Allergy and  
Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

How could the transition process be improved?

Previous Page

Next Page





National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

How did the transition time between R21 and R33 funding affect the progress of your research? (Please check only one.)

- Completely halted my research
- Somewhat slowed my research
- No impact on my research
- Somewhat increased the speed of my research
- Greatly increased the speed of my research

Previous Page

Next Page



SECTION 7: R33 BUDGET GRANT PERIOD

Question 14

Click here to save and continue survey later



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)**  
**Phased Innovation Award Program**  
**Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**R33 BUDGET GRANT PERIOD**

Three years for the R33 phase was sufficient time to expand proof-of-concept to the preclinical or clinical trial stage.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page



SECTION 8: PROGRAM OFFICER MANAGEMENT AND MONITORING

Question 15

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

PROGRAM OFFICER MANAGEMENT AND MONITORING

Expected research progress during the R21 phase was closely tied to milestones.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page





National Institute of  
Allergy and  
Infectious Diseases

**Division of AIDS (DAIDS)**  
**Phased Innovation Award Program**  
**Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

The process to report on grant progress based on the milestones was:

- Very easy
- Somewhat easy
- Somewhat difficult
- Very difficult

From your experience, what made it difficult for you to report on grant progress based on the milestones?

Previous Page

Next Page



[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

The milestones were used to hold me closely accountable on my grant progress.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page

48%

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

I was satisfied with the NIAID Project Officer's progress monitoring.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page

50%

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

During the R21 phase, frequency of communication with my Project Officer was:

- Too frequent
- Appropriate
- Not frequent enough

[Previous Page](#)

[Next Page](#)

52%

[Click here to save and continue survey later](#)



National Institute of Allergy and Infectious Diseases

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Communication with my Project Officer during the R21 phase was helpful.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page



[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

During the R33 phase, frequency of communication with my Project Officer was:

- Too frequent
- Appropriate
- Not frequent enough

[Previous Page](#)

[Next Page](#)



[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

Communication with my Project Officer during the R33 phase was helpful.

- Strongly Agree
- Agree
- Disagree
- Strongly Disagree

Previous Page

Next Page

59%

SECTION 9: CHARACTERISTICS OF THE R21/R33 FUNDING MECHANISM

Question 23

Click here to save and continue survey later



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**CHARACTERISTICS OF THE R21/R33 FUNDING MECHANISM**

Below are some characteristics of the R21/R33 funding mechanism. Please indicate which characteristics you thought were advantageous when you decided to apply for R21/R33 funding. (Please specify other characteristics in the last two rows if needed.)

	Yes (advantageous)	No (not advantageous)
Encouraged innovative, novel research that may be high risk/high impact	<input type="radio"/>	<input type="radio"/>
Required a single application submission and evaluation of the R21 and R33	<input type="radio"/>	<input type="radio"/>
Required inclusion of quantifiable milestones	<input type="radio"/>	<input type="radio"/>
Opportunity to negotiate milestones prior to award	<input type="radio"/>	<input type="radio"/>
Opportunity to continue funding in R33 phase without submitting a new application	<input type="radio"/>	<input type="radio"/>
Did not require preliminary data	<input type="radio"/>	<input type="radio"/>
Availability of multiple application receipt dates	<input type="radio"/>	<input type="radio"/>
<input type="text" value="Enter Other Here"/>	<input type="radio"/>	<input type="radio"/>
<input type="text" value="Enter Other Here"/>	<input type="radio"/>	<input type="radio"/>

Previous Page Next Page





**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Please list below any aspects of the R21/R33 program that you felt were disadvantageous when deciding to apply.

Previous Page

Next Page





National Institute of Allergy and Infectious Diseases

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Please rate your level of agreement with the following statements:  
(Please fill in one for each row.)

	Strongly Agree	Agree	Disagree	Strongly Disagree
The R21/R33 mechanism is a useful method to attract more (or new) investigators to the field (AIDS Vaccine Research/Microbicide Innovation).	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The R21/R33 mechanism is a useful way to support high risk or novel approaches in the field (AIDS Vaccine Research/Microbicide Innovation).	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Previous Page

Next Page



SECTION 10: COLLABORATIONS

Question 26

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

COLLABORATIONS

Has a new collaboration or partnership resulted from your R21/R33 application or award?

- Yes
- No

Previous Page

Next Page

68%



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

In what area was this collaboration(s)? (Please check all that apply.)

- Academia
- Private Industry
- Non-Profit
- Federal Government
- State or Local Government
- Other (Please specify)

Previous Page

Next Page

70%

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

Does this collaboration(s) bring together disciplines or sectors that traditionally do not work together?

- Yes
- No

Previous Page

Next Page



[Click here to save and continue survey later](#)



Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

When did this collaboration(s) occur? (Please check all that apply.)

- During R21 Phase
- During R33 Phase
- Beyond R21/R33 funding

Previous Page

Next Page





Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Has this collaboration(s) resulted in a direct financial contribution to your research?

- Yes
- No

If yes, was the estimated dollar amount:

- Less than \$500K
- Between \$500K and \$1M
- Greater than \$1M

Previous Page

Next Page





National Institute of Allergy and Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016


Has this collaboration(s) contributed in non-financial ways to your research?

- Yes
- No

If Yes, please explain

Previous Page

Next Page



**SECTION 11: OTHER FUNDING**

Question 32



National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016


OTHER FUNDING

Based on your research progress during the R21/R33 award, did you apply for **other NIH funding** (aside from the R21/R33) to continue the line of research of your R21/R33 application?

- Yes
- No

Previous Page

Next Page



Question 32(a)



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

The other NIH funding that I applied for was: (Please check all that apply.)

- In response to a Funding Opportunity Announcement (FOA)
  - Investigator Initiated
- 

Previous Page

Next Page

84%



National Institute of Allergy and Infectious Diseases

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Please list the type(s) of other NIH awards you applied for and complete the following table. (One row per funding request or application; list multiple awards of the same mechanism as R01-1, R01-2, etc.)

	NIH Award Type (e.g. R01, U19)	During which phase of the R21/R33 did you apply for this funding?	Did you receive this funding?	How were the funds distributed to you?
Award 1	<input type="text" value="R01"/>	<input type="text" value="R21"/>	<input type="text" value="Yes"/>	<input type="text" value="Directly to me"/>
Award 2	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Award 3	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Award 4	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Award 5	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Previous Page

Next Page



Question 33

Click here to save and continue survey later



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

Based on your research progress during the R21/R33 award, did you apply for or receive **other, non-NIH funding** to continue the line of research of your R21/R33 application?

- Yes
- No

Previous Page

Next Page

91%

SECTION 12: CONCLUDING COMMENTS

Question 34

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

Division of AIDS (DAIDS)  
**Phased Innovation Award Program  
Customer Satisfaction Survey**

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

CONCLUDING COMMENTS

Please describe any challenges or barriers that you experienced with the R21/R33 program.

Previous Page

Next Page

93%

[Click here to save and continue survey later](#)



National Institute of  
Allergy and  
Infectious Diseases

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

Please list any recommendations you have to improve the design, management, and/or administration of the R21/R33 program.

Previous Page

Next Page

95%

Click here to save and continue survey later



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

## Division of AIDS (DAIDS) Phased Innovation Award Program Customer Satisfaction Survey

Please tell us anything else you think is important to know about your experience with the R21/R33 funding mechanism and process.

Please click [Submit Survey](#) below to complete the survey.

Previous Page

Submit Survey

98%



National Institute of  
Allergy and  
Infectious Diseases

OMB Control Number: 0925-0668  
Expiration Date: 1/31/2016

**Division of AIDS (DAIDS)  
Phased Innovation Award Program  
Customer Satisfaction Survey**

THANK YOU!

Thank you for taking the time to complete this survey.  
Please close your browser window to exit this survey.

---

